Citigroup Inc. Acquires 32,224 Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR)

Citigroup Inc. lifted its holdings in Lifecore Biomedical, Inc. (NASDAQ:LFCR) by 2,311.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 33,618 shares of the company’s stock after purchasing an additional 32,224 shares during the period. Citigroup Inc. owned 0.11% of Lifecore Biomedical worth $254,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. Wynnefield Capital Inc. bought a new position in Lifecore Biomedical during the second quarter valued at about $47,611,000. Greenhaven Road Investment Management L.P. boosted its holdings in Lifecore Biomedical by 15.3% during the third quarter. Greenhaven Road Investment Management L.P. now owns 2,193,333 shares of the company’s stock valued at $16,549,000 after purchasing an additional 290,694 shares in the last quarter. BlackRock Inc. acquired a new stake in Lifecore Biomedical during the second quarter valued at approximately $5,145,000. Visionary Wealth Advisors boosted its holdings in Lifecore Biomedical by 0.4% during the third quarter. Visionary Wealth Advisors now owns 501,334 shares of the company’s stock valued at $3,783,000 after purchasing an additional 2,025 shares in the last quarter. Finally, Geode Capital Management LLC acquired a new stake in Lifecore Biomedical during the second quarter valued at approximately $2,771,000. 83.36% of the stock is currently owned by institutional investors.

Lifecore Biomedical Trading Up 0.2 %

NASDAQ LFCR opened at $5.17 on Thursday. The stock’s 50 day moving average is $7.29 and its two-hundred day moving average is $7.14. The company has a market capitalization of $156.75 million, a price-to-earnings ratio of -1.54 and a beta of 1.07. Lifecore Biomedical, Inc. has a 1-year low of $3.09 and a 1-year high of $11.45.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.